Numaferm

Combining science with an innovative spirit
Founded in 2017 in Duesseldorf, Germany, Numaferm has become a trusted partner in the field of the recombinant expression of peptides, pepteins and proteins. Our team of ~ 30 experts (15 lab + 7 investors people + 8 advisors) is built to solve all challenges along the way from discovery to commercialization. With more than 15 Ph. D. level scientists and cumulated relevant experiences of + 100 years, highest scientific expertise is guaranteed. Our facility of 500 m2 (5,300 ft2) is equipped with state-of-the-art technology ensuring industry-grade processes and GMP/commercial production at third party CMOs. Quality and customer satisfaction is of highest importance and we are operating in accordance to the ISO9001:2015 standards. Our technologies and our operations were recognized by national and international media and awarded with prestigious prices.

to left

Management & Advisory Board

Dr. Anke Caßing

Senior Investment Manager,
High-Tech-Gründerfonds

Dr. Jens Busse

Investment Manager,
Evonik Ventures

Dr. Klaus Binder

CEO & Founder,
Binder Associates

Robert E. W. Hancock

Killam Professor Microbiology / Immunology,
University of British Columbia

Dr. Jürgen Schumacher

Business Angel & Serial Entrepreneur,
i.e. Qiagen and NewLab

Dr. Karl-Heinz Maurer

Chairman of the Board,
CLIB

Prof. Dirk Lütkemeyer

University of Bielefeld,
Co-founder Bibitec

Prof. em. Dr. Dr. h.c. Detlev Riesner

Business Angel & Serial Entrepreneur,
i.e. Qiagen and Evotec

Prof. Dr. Karl-Erich Jaeger

Forschungszentrum Jülich/HHU,
Co-founder evoxx

Prof. Dr. Lutz Schmitt

Chair Biochemistry I,
Heinrich-Heine-Universität Düsseldorf

Alain Scarso, PhD

Peptide CMO expert,
i.e. Polypeptide and Lonza (retired)

Dr. Christian Schwarz

CEO and co-founder,
Numaferm GmbH

Our Investors

Join our team

We appreciate your contributions
View Open Positions